Method for producing placenta extract, and placenta extract
The method addresses the degradation of placenta extract components by using controlled crushing and sterilization to maintain a high concentration of intact extracellular vesicles, ensuring their functionality and stability in cosmetic applications.
Patent Information
- Application Number
- JP2023073383
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-04-27
- Publication Date
- 2024-11-08
AI Technical Summary
Physiologically active substances in placenta extracts are prone to deactivation or denaturation during manufacturing, storage, or use, and extracellular vesicles are easily degraded, affecting their functional efficacy in applications like cosmetics.
A method involving multiple crushing and sterilization steps with controlled crushing forces and sterilization methods to preserve extracellular vesicles, ensuring they remain intact and within a desired particle size range.
The method effectively produces a placenta extract with a high concentration of intact extracellular vesicles, maintaining their functionality and stability, suitable for applications in cosmetics and other products.
Smart Images

Figure 2024158294000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing a placenta extract containing extracellular vesicles, and a placenta extract containing extracellular vesicles. [Background technology]
[0002] Placenta (mammalian placenta) is known to have many functions such as antioxidant properties, collagen production promotion ability, collagenase inhibitory activity, antihypertensive effect, elastase inhibitory effect, and tyrosinase inhibitory effect, and it is expected that placenta will be used as cosmetics, health foods, medical products, etc. (Patent Document 1). These functions are thought to be contributed by physiologically active substances contained in placenta, such as lipids, proteins, nucleic acids (microRNA, messenger RNA, DNA, etc.), and cytokines.
[0003] On the other hand, many physiologically active substances are easily degraded, and it is known that in vivo they are contained in extracellular vesicles. Exosomes, a type of extracellular vesicle, are produced in the process of releasing membrane vesicles, which are formed by the invagination of endosomes formed within cells by endocytosis, into the extracellular space. Exosomes released into the extracellular space function as information transmitters between cells, and it is believed that exosomes act on receptors on the surface of the receiving cell to cause signal transduction, or that the contents of exosomes taken up into the cell function in the receiving cell.
[0004] In addition to exosomes, microvesicles and apoptotic bodies are also known as extracellular vesicles. The difference between them is their particle size (exosomes are 30-200 nm, microvesicles are 100-1000 nm, and apoptotic bodies are 1000-4000 nm) and their production mechanism. Microvesicles are produced by budding directly from the cell membrane and secreted outside the cell, while apoptotic vesicles are produced by budding from the membrane of cells that have undergone apoptosis. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2017-100998 A Summary of the Invention [Problem to be solved by the invention]
[0006] When the above-mentioned physiologically active substances contained in placenta are used in cosmetics, etc., there is a possibility that these physiologically active substances may be inactivated or denatured during the manufacturing process. In addition, even if the extract contains physiologically active substances, if they are not encapsulated in extracellular vesicles, there is a concern that they may be inactivated or denatured during storage or use, and they may not be able to act on the target in cosmetics, etc. On the other hand, the extracellular vesicles themselves are easily decomposed, and destruction or denaturation during the manufacturing process or storage may cause the internal physiologically active substances to be released, which may cause the physiologically active substances to be inactivated or denatured. Therefore, when the function of placenta is expected in cosmetics, etc., it is desirable to have an extract that contains a large amount of extracellular vesicles of the desired particle size.
[0007] The present invention has been made in consideration of the above-mentioned problems, and its main object is to provide a method for producing a placenta extract containing a large amount of extracellular vesicles of a desired particle size, and a placenta extract containing a large amount of extracellular vesicles of a desired particle size. [Means for solving the problem]
[0008] The method for producing the placenta extract of the present invention 1 is as follows: A method for producing a placenta extract containing extracellular vesicles, comprising: A first crushing step of crushing the placenta to obtain a crushed material; A sterilization step of sterilizing the pulverized product obtained by the first pulverization step; A second crushing step of crushing the crushed product after sterilization by the sterilization step; The present invention is characterized by comprising:
[0009] The method for producing a placenta extract according to the present invention 2 comprises the steps of: The method further comprises a contacting step of contacting the placenta before pulverization in the first pulverization step, or the pulverized material obtained in the first pulverization step, with a liquid before the second pulverization step.
[0010] The method for producing a placenta extract according to the present invention 3 comprises the steps of: The contact step is characterized in that the pulverized material sterilized in the sterilization step is brought into contact with the liquid.
[0011] Invention 4 is characterized in that in Invention 1 or Invention 2, the average particle size of extracellular vesicles contained in the placenta extract after pulverization in the second pulverization step is 30 to 300 nm.
[0012] Invention 5 is characterized in that, in Invention 4, the modal particle size of the extracellular vesicles contained in the placenta extract after pulverization in the second pulverization step is 100 to 200 nm.
[0013] The present invention 6 is characterized in that the concentration of extracellular vesicles contained in the placenta extract after the pulverization in the second pulverization step is 1×10 8 It is characterized in that the number of cells per mL or more.
[0014] The seventh invention is characterized in that, in the first invention, the extracellular vesicles are exosomes.
[0015] The present invention 8 is a placenta extract containing extracellular vesicles, The average particle size of the extracellular vesicles is 30 to 300 nm, the modal particle size of the extracellular vesicles is 100 to 200 nm, and the concentration of the extracellular vesicles is 1×10 8 It is characterized in that the number of cells per mL or more. Effect of the Invention
[0016] According to the present invention, by carrying out the sterilization process after the first crushing process, it is possible to efficiently sterilize microorganisms and viruses inside the placenta, suppress damage to the placenta itself, and suppress destruction and denaturation of extracellular vesicles during the manufacturing process. In addition, since the sterilization liquid in the sterilization process contacts the crushed material after the first crushing process, the crushed material is softened, so that the desired crushed material can be obtained even if the crushing force in the subsequent second crushing process is weakened. Furthermore, since the crushing process is performed multiple times, it is possible to weaken the crushing force of each crushing process. Through these, it is possible to suppress the generation of frictional heat associated with the crushing process, and it is possible to suppress the destruction and denaturation of extracellular vesicles, and it is possible to obtain a placenta extract containing a large amount of extracellular vesicles of a desired particle size. [Brief description of the drawings]
[0017] [Figure 1] 1 is a flowchart showing an example of a method for producing a placenta extract. [Diagram 2] FIG. 1 shows the concentration of extracellular vesicles contained in placenta extract. [Diagram 3] FIG. 1 shows the particle size distribution of extracellular vesicles contained in a placenta extract. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] <Production method of placenta extract> The method for producing a placenta extract in the present disclosure (hereinafter also referred to as "the present production method") includes a first crushing step of crushing placenta, a sterilization step of sterilizing the crushed product obtained in the first crushing step, and a second crushing step of crushing the crushed product sterilized in the sterilization step. Each step included in the present production method will be described in detail below.
[0019] <First grinding process> The first pulverization step is a step of pulverizing the placenta, more specifically, a step of dividing the solid size of the placenta to be used as the raw material for the placenta extract into small pieces.
[0020] In this specification, the placenta refers to the placenta of a mammal, for example, human, bovine, porcine, ovine, or equine placenta, although from the viewpoint of safety, the placenta is preferably that of a pig.
[0021] The placenta used in the first crushing step may be used as it is after being removed from the living body, or after being removed from the living body and frozen and thawed, or may be used after being washed. The washing method is not particularly limited, and the placenta may be washed with various chemical solutions, pure water, or other liquids. The liquid used for washing may have the effect of washing away impurities, but it is preferable that the liquid does not contain chemicals from the viewpoint of safety and protecting the functions of physiologically active substances. However, this is not limited to pure water, and may contain a small amount of salt, etc.
[0022] In addition, it is preferable to perform trimming before the above-mentioned washing to remove impurities such as blood vessels, blood, discolored areas, etc. By washing the placenta after trimming, it is expected to have the effect of washing away not only the impurities removed by trimming, but also germs and viruses contained in the cross section of the placenta exposed by trimming.
[0023] The grinding method in the first grinding step is not particularly limited and any known method can be used, such as a ball mill, bead mill, colloid mill, conical mill, disk mill, edge mill, flour mill, hammer mill, pellet mill, cutting mill, roller mill, jet mill, mixer, etc.
[0024] In this first grinding step, a grinding method with a relatively low grinding force (grinding force set by any one or a combination of shear stress, friction force, and grinding frequency) is adopted (for example, a mixer, a disk mill, a cutting mill, or a roller mill is adopted), so that grinding can be performed while suppressing the destruction or denaturation of extracellular vesicles. The grinding time for the first grinding step is set, for example, within 1 minute, preferably within 30 seconds, and more preferably within 10 seconds. Furthermore, the frictional heat generated in the first grinding step is set, for example, to 40°C or less, preferably 30°C or less, and more preferably 20°C or less.
[0025] In particular, in this first pulverization step, it is preferable to limit the fragmentation of the placenta tissue pieces to an extent that each cell is not destroyed, and for example, it is preferable to pulverize so that the fragmented tissue pieces are 1 mm or more, preferably 1 cm or more, and more preferably 3 cm or more. In addition, from the viewpoint of exposing the cross section of the placenta by pulverization, it is preferable to pulverize so that the fragmented tissue pieces are 20 cm or less, preferably 15 cm or less, and more preferably 10 cm or less. It is not necessary that all the fragmented tissue pieces are these sizes, and for example, it is possible to include tissue pieces less than 1 mm and tissue pieces larger than 20 cm, and it is preferable to pulverize so that about 80% (% by number of tissue pieces) of the total are the above sizes.
[0026] In the first crushing step, it is preferable to use no extract or to use as little extract as possible, from the viewpoint of increasing the concentration of extracellular vesicles and from the viewpoint of suppressing the destruction or denaturation of extracellular vesicles by providing a step of removing or reducing (concentrating) the extract. Specifically, it is preferable to set the amount of extract to 10% or less, preferably 5% or less, more preferably 1% or less, based on the mass of the placenta.
[0027] <Sterilization process> The sterilization step is a step of sterilizing the pulverized material obtained by the first pulverization step. More specifically, it is a process for killing or reducing microorganisms and viruses contained inside the placenta, such as the cross section of the pulverized material, blood vessels, and blood. By providing a step of sterilization after the first pulverization step, it is possible to sterilize not only the surface of the placenta but also the microorganisms and viruses contained inside, and the sterilization efficiency can be improved compared to sterilizing only the surface of the placenta. Since the sterilization efficiency is improved compared to the case where the inside of the placenta is sterilized from the surface of the placenta, it is possible to sterilize using a method that reduces the sterilization power and the number of sterilizations, even when trying to obtain the same sterilization effect as when sterilization is performed before pulverization, and it is also possible to reduce damage to the placenta itself. This makes it possible to suppress the destruction and denaturation of extracellular vesicles accompanying the sterilization process.
[0028] The sterilization method is not particularly limited, and may be, for example, sterilization using a solvent such as ethanol, isopropyl alcohol, phenol, cresol, benzalkonium chloride, benzethonium chloride, alkyldiamine ethylglycine hydrochloride, chlorhexidine gluconate, an oxidizing agent, or an acid or alkali, or sterilization by high pressure treatment or heat treatment. However, sterilization by high pressure treatment or heat treatment may cause destruction or denaturation of extracellular vesicles, so sterilization by a solution is preferably adopted. In addition, sterilization by high pressure treatment or heat treatment can be adopted as long as it is performed at, for example, 50°C or less, preferably 30°C or less, and more preferably 20°C or less. The solution used for sterilization is preferably ethanol, citric acid, sodium hypochlorite, or the like, which reduces damage to placenta tissue pieces and suppresses destruction or denaturation of extracellular vesicles, and allows efficient sterilization.
[0029] Sterilization treatment is expected to not only kill microorganisms and viruses, but also to soften the object to be sterilized. In other words, placenta tissue and cell membranes are softened by contact with the solution used for sterilization, high pressure treatment, and heat treatment. This makes it possible to set the crushing force weaker in the second crushing step described below, which is carried out after the sterilization step. This makes it possible to suppress the generation of frictional heat during crushing in the second crushing step, and to suppress the destruction and denaturation of extracellular vesicles.
[0030] In addition to being carried out after the first crushing step, a sterilization treatment may also be carried out before the first crushing step (hereinafter, the step of carrying out a sterilization treatment before the first crushing step is referred to as the "first sterilization step", and the step of carrying out a sterilization treatment after the first crushing step is referred to as the "second sterilization step").
[0031] By providing the first sterilization step, it is possible to sterilize microorganisms, viruses, etc. that are attached to the surface of the placenta. The sterilization method of the first sterilization step is not particularly limited, and the same method as the sterilization method in the second sterilization step can be adopted. However, a sterilization method different from the sterilization method in the second sterilization step may be adopted.
[0032] As described above, by providing a sterilization step before the pulverization step, the softening effect of the sterilization target accompanying the sterilization treatment can be expected. Therefore, by providing the first sterilization step before the first pulverization step, the placenta is softened, so that it is possible to obtain an equivalent pulverized product even if the pulverization force is set weakly in the first pulverization step. Therefore, it is possible to further suppress the destruction and denaturation of extracellular vesicles.
[0033] In this case, the first sterilization step and the second sterilization step may each be performed multiple times, or either one of them may be performed multiple times. For example, the sterilization effect can be further improved by performing sterilization treatment multiple times in both the first sterilization step and the second sterilization step. In addition, the number of times sterilization is performed in the first sterilization step may be greater than the number of times sterilization is performed in the second sterilization step (for example, sterilization is performed multiple times in the first sterilization step and once in the second sterilization step), or the number of times sterilization is performed in the second sterilization step may be greater than the number of times sterilization is performed in the first sterilization step (for example, sterilization is performed once in the first sterilization step and multiple times in the second sterilization step). From the viewpoint of suppressing damage to the placenta itself and destruction or denaturation of extracellular vesicles due to sterilization treatment, at least one of the first sterilization step and the second sterilization step may be performed twice, preferably once.
[0034] The sterilization method and the number of sterilization treatments can be determined, for example, depending on the distribution of microorganisms and viruses contained in the placenta. If the surface of the placenta contains more microorganisms and viruses than the interior of the placenta, the first sterilization step can be a sterilization method and the number of sterilization treatments that have a greater sterilization effect than the second sterilization step, and if the interior of the placenta contains more microorganisms and viruses than the surface of the placenta, the second sterilization step can be a sterilization method and the number of sterilization treatments that have a greater sterilization effect than the first sterilization step.
[0035] In this case, the sterilization method and the number of times of sterilization treatment may be set such that the first sterilization step is a stronger sterilization treatment than the second sterilization step, and the number of times of sterilization treatment is set greater for the second sterilization step than for the first sterilization step, or the sterilization method is a stronger sterilization treatment than the first sterilization step, and the number of times of sterilization treatment is set greater for the first sterilization step than the second sterilization step.
[0036] <Second crushing process> The second grinding step is a step of further grinding the ground product obtained in the first grinding step. More specifically, it is a step of further dividing the solid size of the ground product obtained in the first grinding step into smaller particles, for example, into a gel or paste.
[0037] The method of pulverization in the second pulverization step may be the same as or different from that in the first pulverization step, and may be, for example, a mixer, a disk mill, a cutting mill, or a roller mill.
[0038] In this second pulverization step, more fine fragmentation is required than in the first pulverization step. Therefore, for example, pulverization is performed so that the particle size after pulverization is 1 mm or less, preferably 500 μm or less, more preferably 100 μm or less. If the particle size is larger than 1 mm, the texture and application comfort of the pulverized product may be poor, and the amount of released extracellular vesicles such as exosomes may be reduced. On the other hand, from the viewpoint of suppressing the destruction of extracellular vesicles due to pulverization, for example, pulverization is performed so that the particle size after pulverization is 1 μm or more, preferably 10 μm or more, more preferably 50 μm or more.
[0039] The grinding time for the second grinding step is set to, for example, 5 minutes or less, preferably 2 minutes or less, and more preferably 1 minute or less. Furthermore, the frictional heat generated in the second grinding step is set to, for example, 40° C. or less, preferably 30° C. or less, and more preferably 20° C. or less.
[0040] However, since the sterilization step is provided before the second crushing step, the sterilization target (the crushed product after the first crushing step) is softened by the sterilization step. Therefore, in the second crushing step, it is possible to crush the target to the desired size while relatively weakening the crushing force. Therefore, it is possible to suppress the frictional heat generated and also to suppress the physical destruction of the extracellular vesicles (destruction of the membrane of the extracellular vesicles).
[0041] Furthermore, since the pulverization process is performed in multiple steps as described above, the pulverization force can be set weaker for each step than when the pulverization process is performed in a single step to pulverize the vesicles to a desired state (e.g., gel or paste). This also makes it possible to suppress the generation of frictional heat associated with pulverization and physical destruction of the extracellular vesicles.
[0042] In the second crushing step, it is preferable to use no extract or to use as little extract as possible, from the viewpoint of increasing the content concentration of extracellular vesicles and from the viewpoint of suppressing the destruction or denaturation of extracellular vesicles by providing a subsequent step of removing or reducing (concentrating) the extract. Specifically, it is preferable to set the amount of extract to 10% or less, preferably 5% or less, more preferably 1% or less, based on the mass of the placenta.
[0043] In addition, the state and size of the pulverized material obtained in the second pulverization step does not exclude the provision of a pulverization step subsequent to the second pulverization step, and a further pulverization step may be provided.
[0044] <Other processes> In addition to the above-mentioned first pulverization step, sterilization step, and second pulverization step, the present production method may further include steps different from the first pulverization step, sterilization step, and second pulverization step (hereinafter, also referred to as "other steps"). Examples of the other steps include a contact step in which the extraction target (placenta, pulverized placenta, etc.) is brought into contact with a liquid.
[0045] (contact process) The contact step is a step for increasing the extraction efficiency of extracellular vesicles and the liberation rate of extracellular vesicles by bringing the liquid into contact with the object to be extracted to soften the placental tissue pieces and cell membranes. The method for bringing the liquid into contact with the object to be extracted may be a method of spraying the liquid on the object to be extracted, or a method of immersing the object to be extracted in the liquid. When the object to be extracted is immersed in the liquid, it is preferable that the object to be extracted is immersed in the liquid by 50% or more, preferably by 70% or more, and more preferably by 100%.
[0046] From the viewpoint of increasing the extraction efficiency, the contact step is preferably carried out before at least one of the first and second crushing steps, for example, before the second crushing step, and more preferably before the second crushing step and after the sterilization step (second sterilization step).
[0047] The liquid used in the contact step is not particularly limited, and may be, for example, water, or preferably a liquid containing an osmotic pressure adjusting substance (osmotically effective substance, osmonite). As the osmotic pressure adjusting substance, inorganic ions (potassium ions, chloride ions), monosaccharides, disaccharides, polyhydric alcohols, amino acids, methylammoniums, ureas, etc. can be used. By using a liquid containing an osmotic pressure adjusting substance to carry out the contact step with the liquid, it is possible to further increase the extraction efficiency in the contact step.
[0048] From the viewpoint of increasing the extraction efficiency, the contact step may be, for example, 1 hour or more, preferably half a day (12 hours) or more, more preferably 1 day (24 hours) or more, whereas from the viewpoint of suppressing the increase of microorganisms or viruses during the contact step, the contact step may be, for example, within 1 week, preferably within 3 days, more preferably within 1.5 days.
[0049] The timing of carrying out the contact step is not particularly limited, but if the contact step is carried out after the sterilization step, the proliferation of microorganisms and viruses during the contact step can be suppressed.
[0050] In addition, if the contact step is performed before at least one of the first and second crushing steps, the placenta softens, thereby improving the crushing efficiency of each crushing step. Therefore, the crushing force during crushing can be set to a low level, and the generation of frictional heat associated with crushing can be suppressed, and crushing can be performed while suppressing the destruction and denaturation of extracellular vesicles. In particular, the second crushing step is a crushing step that requires finer particles, and by setting a contact step before the second crushing step, it is possible to achieve the desired fineness (gelation) for the final product while setting the crushing force of the second crushing step to a low level. In this case, from the viewpoint of simplifying the manufacturing process and suppressing the destruction and denaturation of extracellular vesicles, it is preferable to set a contact step before the second crushing step of the first and second crushing steps, and it is preferable to set a contact step in which the crushed product obtained by the first crushing step is brought into contact with a liquid before the second crushing step.
[0051] Furthermore, when the contact step is performed by immersion and a liquid containing an osmotic pressure adjusting substance is used for the immersion, a step of washing the object to be immersed with the liquid before the immersion may be provided, which makes it possible to stabilize the concentration of the osmotic pressure adjusting substance used for the immersion.
[0052] Other steps include, in addition to the above, a step of thawing the raw material, a step of washing, a step of purifying, a step of freezing the placenta extract, and the like.
[0053] (Thaw process) The thawing step is a step of thawing the placenta used as a raw material when it has been stored frozen.
[0054] From the viewpoint of preventing the destruction or denaturation of the extracellular vesicles, the thawing temperature is, for example, 30° C. or lower, preferably 20° C. (room temperature) or lower, more preferably 15° C. or lower. In addition, the thawing method is preferably, for example, without using a liquid such as water (without contact with liquid) to prevent the outflow of the extracellular vesicles.
[0055] (Cleaning process) The washing process is a process for washing away impurities such as blood, as well as attached microorganisms and viruses. The liquid used for washing may have the effect of washing away the object, but it is preferable that the liquid does not contain chemicals from the viewpoint of safety and protecting the functions of physiologically active substances. However, this is not limited to pure water, and may contain a small amount of salt, etc.
[0056] The number of washing steps and the washing method may be different depending on the steps to be performed. For example, when washing is performed after a sterilization step, it is recommended to perform the washing for example twice, preferably three times, more preferably four times, from the viewpoint of safety, such as washing off the solvent used in the sterilization step. In addition, when performing multiple washings, it is possible to increase the washing efficiency by removing the liquid used for washing after each washing.
[0057] (purification process) The purification process is a process for removing impurities (such as microorganisms and viruses, their carcasses, and cell fragments) contained therein. Examples of purification processes include fractionation using chromatography, filtration using filter paper, membrane filters, ultrafiltration membranes, etc., drying, pH adjustment, deodorization, decolorization, long-term static storage, etc., and any of these processes can be arbitrarily selected and combined.
[0058] (Freezing / preservation process) The freezing step is a step for freezing and storing the pulverized product (placenta extract) obtained by the second pulverization step. This does not deny that another step may be included between the second pulverization step and the freezing step. For example, the freezing and storing step may be a step of freezing and storing the product after the second pulverization step by providing another step such as a sterilization step, a purification step, or a pulverization step after the second pulverization step.
[0059] The freezing temperature is, for example, 0°C or lower, preferably -10°C or lower, more preferably -30°C or lower, from the viewpoint of suppressing the increase of microorganisms and viruses. The frozen placenta extract may be stored at the same temperature, for example, or may be stored at a temperature different from the freezing temperature (for example, a temperature higher than the freezing temperature). However, if it melts during storage, there is a concern that the quality of the final product may deteriorate, so it is preferable to store it at 0°C or lower.
[0060] Next, one embodiment of the present manufacturing method will be described with reference to the flow chart of FIG.
[0061] First, the placenta that has been collected, frozen, and stored is thawed at 20°C (room temperature) without being immersed in water or other liquids (Step S10). After thawing, it is trimmed to remove impurities such as blood vessels, blood, and discolored areas (Step S20). After trimming, it is washed with running water at 20°C to remove impurities after trimming and any attached microorganisms or viruses (Step S30).
[0062] After washing, the placenta is broken down into tissue pieces of 3 cm or more and 10 cm or less in size in a first crushing step (step S40). The crushed material obtained in the first crushing step is sterilized using ethanol, citric acid, sodium hypochlorite, etc. (step S50). Then, impurities such as blood eluted in the first crushing step, microorganisms and viruses sterilized in the sterilization step, and the solvent used for sterilization are washed away with running water (step S60).
[0063] Next, the washed placenta is immersed in a liquid containing an osmotic pressure adjusting substance such as sodium chloride (step S70). After immersion, in a second crushing step (step S80), the placenta is crushed, for example, into a gel-like state to obtain a placenta extract. The obtained placenta extract is then frozen and stored.
[0064] <Placenta extract> According to the present production method described above, it is possible to obtain a placenta extract containing extracellular vesicles having an average particle size of 30 to 300 nm (hereinafter also referred to as "the present extract").
[0065] In this specification, the average particle size means the average value of the particle size values of extracellular vesicles measured by the nanosite tracking method.
[0066] Furthermore, the extracellular vesicles of the present extract may contain, for example, any one of exosomes, microvesicles, and apoptotic bodies, and may also contain a plurality of or all of these.
[0067] The particle size of each extracellular vesicle contained in the extract is in the range of about 30 to 600 nm. The lower limit of the average particle size of the extracellular vesicles is preferably 50 nm or more, more preferably 75 nm or more. The upper limit of the average particle size of the extracellular vesicles is preferably 270 nm or less, more preferably 250 nm or less.
[0068] The placenta extract has a mode particle size (most frequent particle size) of 100 to 200 nm. The lower limit of the mode particle size is preferably 110 nm or more, more preferably 115 nm or more. The upper limit of the mode particle size is preferably 180 nm or less, more preferably 150 nm or less.
[0069] In this specification, the modal particle size is the particle size at which the frequency distribution value of the particle size of extracellular vesicles measured by the nanosite tracking method is maximum, and is the particle size that shows the highest peak in the frequency distribution graph.
[0070] As described above, exosomes are extracellular vesicles with a diameter of about 30 to 200 nm, microvesicles are extracellular vesicles with a diameter of about 100 to 1000 nm, and apoptotic bodies are extracellular vesicles with a diameter of about 1000 to 4000 nm. Therefore, the extract mainly contains exosomes as extracellular vesicles.
[0071] The content of extracellular vesicles in the present extract may be any content that can be expected to fully utilize the functions of the physiologically active substances contained in the extracellular vesicles. Specifically, the content of extracellular vesicles is 1×10 8 / mL or more, preferably 1 × 10 9 / mL or more, more preferably 1×10 10 The maximum content is not particularly limited, but is preferably 1×10 20 / mL or less, preferably 1 × 10 19 / mL or less, more preferably 1×10 18 / mL or less.
[0072] In this specification, the content of extracellular vesicles indicates the concentration calculated from the number of extracellular vesicle particles measured by the nanosite tracking method.
[0073] The extract may further contain components other than the extracellular vesicles (hereinafter, also referred to as "other components"). Examples of the other components include pH adjusters (citric acid, sodium citrate, potassium hydroxide, sodium hydroxide, etc.), fragrances, refreshing agents (menthol, peppermint oil, camphor, etc.), anti-inflammatory agents (salicylic acid, glycyrrhizic acid or its salts, glycyrrhetinic acid, allantoin, etc.), bactericides (chlorhexidine gluconate, isopropylmethylphenol, etc.), preservatives (parabens (methylparaben, butylparaben, propylparaben, etc.), benzoic acid or its salts, phenoxyethanol, etc.), moisturizers (hyaluronic acid or its salts, chondroitin sulfate, polyhydric alcohols (glycerin, diglycerin, 1,3-butylene glycol, propylene glycol, 1,2-pentanediol, etc.), amino acids (L-serine, L-proline, L-hydroxypropyl esters, L-amino acids ... Examples of the ingredients include oleaginous oleaginous extracts, extracts of various plants and animals (such as peony, licorice, rosemary, sage, etc.), vitamins (retinol palmitate, ascorbic acid, thiamine nitrate, cyanocobalamin, biotin, riboflavin, nicotinamide, etc.), antioxidants (dibutylhydroxytoluene, sodium pyrosulfite, tocopherol, sodium edetate, ascorbic acid, isopropyl gallate, etc.), solubilizing agents (various vegetable oils, various animal oils, alkyl glyceryl ethers, hydrocarbons, etc.), metabolic activators, gelling agents (water-soluble polymers (carboxyvinyl polymers, hydroxyethyl cellulose, hydroxypropyl methylcellulose, etc.), oil-based gelling agents (inulin stearate, dextrin palmitate, etc.), adhesives, etc. The content of other ingredients can be appropriately set according to each compound within a range that does not impair the effects of the present disclosure.
[0074] The extract can be used for applications such as cosmetics, health foods, functional foods, quasi-drugs, medicines, etc. The method of use may be, for example, oral administration, internal administration, external administration, or injection. EXAMPLES
[0075] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples. In the examples and comparative examples, "%" is based on mass unless otherwise specified.
[0076] 1. Manufacturing method of placenta extract and purification of extracellular vesicles [Example 1] The placenta extract was produced according to the flow chart in FIG.
[0077] The obtained placenta extract extracellular vesicles were purified and then subjected to nanosite analysis. For purification, MagCapture Exosome Isolation Kit PS Ver.2 (Wako Code 290-84103) was used. Specifically, after capturing the extracellular vesicles in a metal ion-dependent manner using a phosphatidylserine binding molecule, the extracellular vesicles were eluted with a chelating agent (Exoxome Elution Buffer) to prepare a test solution.
[0078] [Comparative Examples 1 to 3] The commercially available placenta extracts were used as Comparative Examples 1 to 3. Comparative Example 1 was a placenta extract manufactured by Company A, Comparative Example 2 was a placenta extract manufactured by Company B, and Comparative Example 3 was a placenta extract manufactured by Company C. All of Comparative Examples 1 to 3 were placenta extracts extracted by heat treatment. For these Comparative Examples 1 to 3, the extracellular vesicles were purified in the same manner as in Example 1 above, and then nanosite analysis was performed. For purification, MagCapture Exosome Isolation Kit PS Ver.2 (Wako Code 290-84103) was used. Specifically, the extracellular vesicles were captured in a metal ion-dependent manner using a phosphatidylserine binding molecule, and then the extracellular vesicles were eluted with a chelating agent (Exoxome Elution Buffer) to prepare a test solution.
[0079] NanoSight LM10 (Malvern Panalyticai) was used for the nanosite analysis of Examples and Comparative Examples 1 to 3. Each of the test solutions was diluted with MillQ water, and images were taken 5 times for 60 seconds under the image acquisition condition of Camera Level 13, and the particle diameter and particle concentration were calculated by image analysis.
[0080] 2. Evaluation As shown in FIG. 2, the placenta extract of Example 1 had a concentration of 2.18×10 10 It was confirmed that the particles contained extracellular vesicles at a particle concentration of 0.10×10 / mL. In contrast, the particle concentrations of extracellular vesicles in Comparative Example 1, Comparative Example 2, and Comparative Example 3 were almost 0, and it was confirmed that no extracellular vesicles were contained, or even if they were contained, the amount was very small. Specifically, Comparative Example 1 contained 0.10×10 10 / mL, and Comparative Example 2 was 0.13 × 10 10 / mL, and Comparative Example 3 was 0.10 × 10 10 / mL.
[0081] Considering that physiologically active substances are contained and protected in extracellular vesicles such as exosomes and microvesicles as described above, it can be expected that the greater the amount of extracellular vesicles contained, the greater the amount of the physiologically active substance contained, and that the inactivation or denaturation of the physiologically active substance is suppressed.
[0082] As shown in FIG. 3, extracellular vesicles with a particle size distribution with multiple peaks over the range of 30 to 600 nm were confirmed in this placenta extract. Therefore, it is considered that this placenta extract contains extracellular vesicles with many particle sizes. As shown in Table 1, the average particle size was 210 nm (standard deviation 117 nm), and the mode particle size was 143 nm. It was confirmed that the particle size was particularly large in the range of 30 to 300 nm, with 83.5% of the total being 30 to 300 nm, 75.6% being 30 to 240 nm, and 63.8% being 30 to 200 nm.
[0083] [Table 1]
[0084] The modal particle size of this placenta extract indicates the particle size of extracellular vesicles classified as exosomes, and it was confirmed that this placenta extract contains a particularly large amount of extracellular vesicles classified as exosomes.
[0085] As mentioned above, extracellular vesicles are classified into exosomes, microvesicles, and apoptotic bodies according to particle size, and it is believed that their generation mechanisms are different, and the physiologically active substances and functions contained therein are also different. Therefore, the fact that extracellular vesicles with multiple particle sizes have been confirmed as described above makes it expected that the placenta extract based on the manufacturing method of the present invention will have more diverse physiologically active substances or more diverse functions.
Claims
1. A method for producing a placenta extract containing extracellular vesicles, comprising: A first pulverization step of pulverizing the placenta to obtain a pulverized material; A sterilization step of sterilizing the pulverized material obtained by the first pulverization step; A second crushing step of crushing the crushed material after the sterilization step; A method for producing a placenta extract comprising the steps of:
2. 2. The method for producing a placenta extract according to claim 1, further comprising a contacting step of contacting the placenta before being crushed in the first crushing step, or the crushed material obtained in the first crushing step, with a liquid before the second crushing step.
3. The method for producing a placenta extract according to claim 2, wherein in the contacting step, the pulverized product sterilized in the sterilizing step is brought into contact with the liquid.
4. The method for producing a placenta extract according to claim 1 or 2, wherein the average particle size of extracellular vesicles contained in the placenta extract after the pulverization in the second pulverization step is 30 to 300 nm.
5. The method for producing a placenta extract according to claim 4, wherein the modal particle size of the extracellular vesicles contained in the placenta extract after the pulverization in the second pulverization step is 100 to 200 nm.
6. The concentration of extracellular vesicles contained in the placenta extract after the second crushing step is 1×10 8 The method for producing a placenta extract according to claim 1, wherein the concentration of the placenta extract is 1 / mL or more.
7. The method for producing a placenta extract according to claim 1, wherein the extracellular vesicles are exosomes.
8. Contains extracellular vesicles, The average particle size of the extracellular vesicles is 30 to 300 nm, the modal particle size of the extracellular vesicles is 100 to 200 nm, and the concentration of the extracellular vesicles is 1×10 8 A placenta extract having a density of 100 / mL or more.
Citation Information
Patent Citations
Placenta extract and method for producing placenta extract
JP2017100998A
